Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Phase 1/2
40
about 3.9 years
18+
1 site in FL
What this study is about
This trial is testing a new treatment for people with metastatic pancreatic cancer. The treatment involves combining nab-paclitaxel, cisplatin, gemcitabine, and tumor treatment fields (TTF). This is a Phase 1/2 trial that will last about 1430 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Modified GCN+TTF treatment
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Safety of (m)-GCN+TTF
Secondary: Overall Response Rate (ORR), Overall Survival (OS), Progression-free Survival (PFS), Quality of Life - EORTC QLQ-C30, Time to Progression (TTP)
Oncology